![2,5-Dichloro-N-[2-[(1-methylethyl)sulfonyl]phenyl]-4-pyrimidinamine](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F3D%2Fthumb-webp%2FFD75047.webp&w=3840&q=75)
Información del producto
Nombre:2,5-Dichloro-N-[2-[(1-methylethyl)sulfonyl]phenyl]-4-pyrimidinamine
Marca:Biosynth
Descripción:Ceritinib is a small molecule that inhibits the activity of tyrosine kinases, including c-Kit and PDGFR. It has been shown to have potent in vitro activity against a broad range of solid tumours and has been approved by the US FDA for use in patients with non-small cell lung cancer (NSCLC) who have progressed following at least one platinum-based chemotherapy regimen.
Ceritinib binds to c-Kit and PDGFR and inhibits their ability to phosphorylate downstream targets, which prevents many cellular processes from occurring. Ceritinib also inhibits the proliferation of tumour cells by interfering with their ability to form new blood vessels. This drug can be used as an adjuvant treatment for NSCLC after at least one platinum-based chemotherapy regimen.
Ceritinib binds to c-Kit and PDGFR and inhibits their ability to phosphorylate downstream targets, which prevents many cellular processes from occurring. Ceritinib also inhibits the proliferation of tumour cells by interfering with their ability to form new blood vessels. This drug can be used as an adjuvant treatment for NSCLC after at least one platinum-based chemotherapy regimen.
Aviso:Nuestros productos están destinados únicamente para uso en laboratorio. Para cualquier otro uso, por favor contáctenos.
Propiedades químicas
Peso molecular:346.23 g/mol
Fórmula:C13H13Cl2N3O2S
Pureza:Min. 95%